After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Kong, Jian ^a   Kong, Lingqun ^b   Kong, Jinge ^c   Ke, Shan ^a   Gao, Jun ^a   Ding, Xuemei ^a   Zheng, Lemin ^c   Sun, Huichuan ^b   Sun, Wenbing ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Hepatocellular carcinoma; Invasiveness; Metastasis; Radiofrequency ablation; Tumor associated endothelial cells

Indexed keywords

CXCL1 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; STAT3 PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CANCER INVASION; CARCINOMA CELL; CELL ACTIVITY; CELL ADHESION; CELL INTERACTION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HCCLM3; CELL STRAIN HEPG2; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEAT TREATMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MINIMAL RESIDUAL DISEASE; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; SIGNAL TRANSDUCTION; TISSUE SECTION; TUMOR ASSOCIATED ENDOTHELIAL CELL; TUMOR VASCULARIZATION; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SHAPE; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GREEN FLUORESCENT PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84869204783     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-230     Document Type: Article

References (46)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 10.1016/S0140-6736(11)61347-0, 22353262.
2. Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, Wolfgang CL, Segev DL, Choti MA, Pawlik TM. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol 2011, 29:619-625. 10.1200/JCO.2010.30.8650, 21205759.
3. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, Silini EM, Dionigi P, Calliada F, Quaretti P, Tinelli C. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011, 53:136-147. 10.1002/hep.23965, 20967759.
4. Nijkamp MW, van der Bilt JD, de Bruijn MT, Molenaar IQ, Voest EE, van Diest PJ, Kranenburg O, Borel Rinkes IH. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg 2009, 249:814-823. 10.1097/SLA.0b013e3181a38ef5, 19387320.
5. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012, 57:794-802. 10.1016/j.jhep.2012.05.007, 22634125.
6. Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka SI, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res 2012, 42:1058-1064. 10.1111/j.1872-034X.2012.01025.x, 22583706.
7. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007, 72(Suppl 1):72-75.
8. Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol 2004, 10:1137-1140.
9. Kong J, Pan B, Ke S, Dong S, Li X, Zhou A, Zheng L, Sun WB. Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1alpha/VEGFA. PLoS One 2012, 7:e37266. 10.1371/journal.pone.0037266, 3352883, 22615958.
10. Ke S, Ding XM, Kong J, Gao J, Wang SH, Cheng Y, Sun WB. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med 2010, 8:73. 10.1186/1479-5876-8-73, 2917410, 20667141.
11. Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C, Suzuki M, Itoh F. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int 2008, 2:116-123. 10.1007/s12072-007-9040-3, 2716878, 19669287.
12. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. 10.1038/nrc2618, 3251309, 19279573.
13. von Breitenbuch P, Kohl G, Guba M, Geissler E, Jauch KW, Steinbauer M. Thermoablation of colorectal liver metastases promotes proliferation of residual intrahepatic neoplastic cells. Surgery 2005, 138:882-887. 10.1016/j.surg.2005.05.006, 16291389.
14. Nikfarjam M, Muralidharan V, Christophi C. Altered growth patterns of colorectal liver metastases after thermal ablation. Surgery 2006, 139:73-81. 10.1016/j.surg.2005.07.030, 16364720.
15. Nijkamp MW, Hoogwater FJ, Steller EJ, Westendorp BF, van der Meulen TA, Leenders MW, Borel Rinkes IH, Kranenburg O. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol 2010, 53:1069-1077. 10.1016/j.jhep.2010.04.040, 20832890.
16. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003, 17:1159-1161.
17. Knipe L, Meli A, Hewlett L, Bierings R, Dempster J, Skehel P, Hannah MJ, Carter T. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood 2010, 116:2183-2191. 10.1182/blood-2010-03-276170, 2951859, 20538801.
18. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, Shinohara N, Nonomura K, Klagsbrun M, Shindoh M. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009, 175:2657-2667. 10.2353/ajpath.2009.090202, 2789618, 19875502.
19. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004, 64:8249-8255. 10.1158/0008-5472.CAN-04-1567, 15548691.
20. Liang Y, Li WW, Yang BW, Tao ZH, Sun HC, Wang L, Xia JL, Qin LX, Tang ZY, Fan J, Wu WZ. Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma. Int J Cancer 2012, 130:1745-1754. 10.1002/ijc.26166, 21544813.
21. Yang BW, Liang Y, Xia JL, Sun HC, Wang L, Zhang JB, Tang ZY, Liu KD, Chen J, Xue Q, Gao DM, Wu WZ. Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur J Gastroenterol Hepatol 2008, 20:1077-1084. 10.1097/MEG.0b013e3283050a67, 19047839.
22. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846. 10.1158/1078-0432.CCR-08-2780, 19638466.
23. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52:762-773. 10.1002/hep.23725, 20564355.
24. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007, 100:782-794. 10.1161/01.RES.0000259593.07661.1e, 17395884.
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31. 10.1038/nm0195-27, 7584949.
26. Wang JH, Wu QD, Bouchier-Hayes D, Redmond HP. Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. Cancer 2002, 94:2745-2755. 10.1002/cncr.10520, 12173346.
27. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292. 10.1016/j.cell.2011.09.024, 3261217, 22000009.
28. Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 2008, 14:1217-1224. 10.2174/138161208784246072, 18473869.
29. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, : .
30. Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, DeNapoli T, Parekh DJ, Gorin Y, Block K. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One 2012, 7:e30712. 10.1371/journal.pone.0030712, 3267761, 22303451.
31. Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS One 2011, 6:e23317. 10.1371/journal.pone.0023317, 3149645, 21826248.
32. Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier C, Vassy R, Martin L, Schischmanoff PO, Gattegno L, Oudar O, Sutton A, Charnaux N. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer 2010, 126:1095-1108.
33. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA, Albelda SM. Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 2011, 44:230-237. 10.1165/rcmb.2010-0080OC, 3049234, 20395632.
34. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999, 5:1369-1379.
35. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC, Fan ST. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003, 9:5996-6001.
36. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, Koelbl H. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 2004, 25:14-17. 10.1159/000077718, 15192307.
37. Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS, Entschladen F. Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res 2012, 10:197-207. 10.1158/1541-7786.MCR-11-0130, 22127496.
38. Ogata H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Ito Y, Fujita M, Tsubaki M, Kato H, Fujimori T, Fukui H. GROalpha promotes invasion of colorectal cancer cells. Oncol Rep 2010, 24:1479-1486.
39. Daneker GW, Lund SA, Caughman SW, Staley CA, Wood WC. Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression. Clin Exp Metastasis 1996, 14:230-238.
40. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997, 71:612-619. 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D, 9178816.
41. Neeson PJ, Thurlow PJ, Jamieson GP, Bradley C. Lymphocyte-facilitated tumour cell adhesion to endothelial cells: the role of high affinity leucocyte integrins. Pathology 2003, 35:50-55.
42. Yamada M, Yanaba K, Hasegawa M, Matsushita Y, Horikawa M, Komura K, Matsushita T, Kawasuji A, Fujita T, Takehara K, Steeber DA, Tedder TF, Sato S. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. Clin Exp Immunol 2006, 143:216-227. 10.1111/j.1365-2249.2005.02989.x, 1809598, 16412045.
43. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184-192. 10.1038/nrc1819, 16453012.
44. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21:159-168. 10.1038/cr.2010.183, 3193410, 21187858.
45. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
46. Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology 2011, 53:1932-1942. 10.1002/hep.24291, 21391225.